News for HBM Holdings Limited (2142.HK)

CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that the Company and HBM Holdings Limited ('Harbour BioMed') (together with the Company, the 'Licensors'), have entered into an exclusive license agreement (the 'License Agreement') with Windward Bio AG ('Windward Bio') for SKB378/HBM9378[1], an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) jointly developed by the Licensors.

Key Takeaways: Sichuan Biokin has been using proceeds from generic drug sales to develop novel oncology drugs, but government procurement policies in China have slowed its revenue stream while R&D spending is on the rise The company has put six ADCs into around 60 clinical trials of which nine are at the Phase Three stage

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech  for an initial sum of $53 million and milestone payments of up to $1.05 billion

HBM Holdings boosted its revenue by 48% in the first half of this year through licensing-out partnerships and by providing R&D services.

CAMBRIDGE, Mass., Oct. 13, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development...

/PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of...

/PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of...

/PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge antibody technology innovation and provider of...